$BPTH
BIO-PATH HOLDINGS, INC.

2017 Q1 Form 10-Q Financial Statement

#000114420417026081 Filed on May 10, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $970.0K $850.0K
YoY Change 14.12% 7.59%
% of Gross Profit
Research & Development $1.026M $1.020M
YoY Change 0.59% 72.01%
% of Gross Profit
Depreciation & Amortization $33.00K $10.00K
YoY Change 230.0% 0.0%
% of Gross Profit
Operating Expenses $1.996M $1.869M
YoY Change 6.8% 35.53%
Operating Profit -$1.996M -$1.869M
YoY Change 6.8% 35.53%
Interest Expense $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.599M $2.000K
YoY Change 79850.0% -50.0%
Pretax Income -$400.0K -$1.870M
YoY Change -78.61% 36.5%
Income Tax
% Of Pretax Income
Net Earnings -$397.0K -$1.867M
YoY Change -78.74% 35.78%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$833.3K -$4.156M
COMMON SHARES
Basic Shares Outstanding 95.65M shares 89.76M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.110M $6.470M
YoY Change 9.89% -48.03%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $1.240M $1.360M
YoY Change -8.82% 183.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.350M $7.830M
YoY Change 6.64% -39.49%
LONG-TERM ASSETS
Property, Plant & Equipment $872.0K $62.00K
YoY Change 1306.45% -39.71%
Goodwill
YoY Change
Intangibles $889.0K $1.050M
YoY Change -15.33% -13.28%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.760M $1.116M
YoY Change 57.71% -14.81%
TOTAL ASSETS
Total Short-Term Assets $8.350M $7.830M
Total Long-Term Assets $1.760M $1.116M
Total Assets $10.11M $8.946M
YoY Change 13.01% -37.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $90.00K $201.0K
YoY Change -55.22% 151.25%
Accrued Expenses $610.0K $699.0K
YoY Change -12.73% 29.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $710.0K $900.0K
YoY Change -21.11% 46.05%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.310M
YoY Change
Total Long-Term Liabilities $1.310M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $710.0K $900.0K
Total Long-Term Liabilities $1.310M $0.00
Total Liabilities $2.020M $900.0K
YoY Change 124.44% 46.05%
SHAREHOLDERS EQUITY
Retained Earnings -$27.25M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.090M $8.050M
YoY Change
Total Liabilities & Shareholders Equity $10.11M $8.950M
YoY Change 12.96% -37.19%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$397.0K -$1.867M
YoY Change -78.74% 35.78%
Depreciation, Depletion And Amortization $33.00K $10.00K
YoY Change 230.0% 0.0%
Cash From Operating Activities -$1.840M -$2.380M
YoY Change -22.69% 68.79%
INVESTING ACTIVITIES
Capital Expenditures $424.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$424.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -$1.840M -2.380M
Cash From Investing Activities -$424.0K
Cash From Financing Activities
Net Change In Cash -$2.264M -2.380M
YoY Change -4.87% 68.79%
FREE CASH FLOW
Cash From Operating Activities -$1.840M -$2.380M
Capital Expenditures $424.0K
Free Cash Flow -$2.264M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
40000 USD
CY2016Q1 us-gaap Depreciation
Depreciation
10000 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
51000 USD
CY2017Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
12000 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
12000 USD
CY2017Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1310000 USD
CY2016Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2906000 USD
CY2016Q1 us-gaap Cash
Cash
6473000 USD
CY2017Q1 us-gaap Revenues
Revenues
0 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1026000 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
970000 USD
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000 USD
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1599000 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
1996000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1996000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-397000 USD
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
95645000 shares
CY2016Q1 us-gaap Revenues
Revenues
0 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1020000 USD
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
849000 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
1869000 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1869000 USD
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000 USD
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-1867000 USD
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89763000 shares
CY2016Q4 bpth Accrued License Maintenance Fee
AccruedLicenseMaintenanceFee
100000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
100000 USD
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1596000 USD
CY2016Q4 bpth Accrued Vacation And Bonus
AccruedVacationAndBonus
400000 USD
CY2017Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1310000 USD
CY2017Q1 bpth Accrued License Maintenance Fee
AccruedLicenseMaintenanceFee
100000 USD
CY2017Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
1300000 USD
CY2017Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
1600000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
614000 USD
CY2017Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
889000 USD
CY2016Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2906000 USD
CY2017Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-1596000 USD
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0149 pure
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.08 pure
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0209 pure
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1 pure
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
929000 USD
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
571000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-37000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2381000 USD
CY2016Q1 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-2381000 USD
CY2015Q4 us-gaap Cash
Cash
8854000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1000 USD
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
424000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-424000 USD
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
114000 USD
CY2016Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2016Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5882352 shares
CY2016Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
9300000 USD
CY2016Q4 us-gaap Other Inventory
OtherInventory
400000 USD
CY2017Q1 us-gaap Other Inventory
OtherInventory
400000 USD
CY2017Q1 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
100000 USD
CY2016Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
100000 USD
CY2017Q1 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
100000 USD
CY2017Q1 bpth Accrued Vacation And Bonus
AccruedVacationAndBonus
200000 USD
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2017Q1 bpth Drug Product Testing Agreement Consideration To Be Paid In Stages
DrugProductTestingAgreementConsiderationToBePaidInStages
100000 USD
CY2017Q1 bpth Drug Supplier Commitments Development
DrugSupplierCommitmentsDevelopment
100000 USD
CY2017Q1 us-gaap Other Commitment
OtherCommitment
700000 USD
CY2017Q1 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
100000 USD
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
100000 USD
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
872000 USD
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
95000 USD
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95645000 shares
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95645000 shares
CY2017Q1 bpth Accrued Clinical And Preclinical
AccruedClinicalAndPreclinical
100000 USD
CY2017Q1 bpth Accrued Laboratory Expense
AccruedLaboratoryExpense
100000 USD
CY2016Q4 bpth Accrued Laboratory Expense
AccruedLaboratoryExpense
200000 USD
CY2016Q4 bpth Accrued Clinical And Preclinical
AccruedClinicalAndPreclinical
200000 USD
CY2016Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
4600000 USD
CY2016Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2900000 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7067000 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7549000 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5505000 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
482000 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.33
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.29
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.01
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.80
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200000 USD
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
900000 USD
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2100000 USD
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y9M18D

Files In Submission

Name View Source Status
0001144204-17-026081-index-headers.html Edgar Link pending
0001144204-17-026081-index.html Edgar Link pending
0001144204-17-026081.txt Edgar Link pending
0001144204-17-026081-xbrl.zip Edgar Link pending
bpth-20170331.xml Edgar Link completed
bpth-20170331.xsd Edgar Link pending
bpth-20170331_cal.xml Edgar Link unprocessable
bpth-20170331_def.xml Edgar Link unprocessable
bpth-20170331_lab.xml Edgar Link unprocessable
bpth-20170331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pg12img1_10q.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v465718_10q.htm Edgar Link pending
v465718_ex31.htm Edgar Link pending
v465718_ex32.htm Edgar Link pending